All Stories

  1. Cardiac amyloidosis: consensus of the Eurasian Association of Cardiologists (EAC)
  2. Efficacy and Safety of Sglt-2 Inhibitors In Renal Allograft Recipients: an Open-Label, Single-Center Prospective Study
  3. The Effectiveness and Profitability of Different Antithrombotic Therapy Regimens in Patients with Type 2 Diabetes Mellitus During 1 Year of Follow-Up after an Exacerbation of Coronary Heart Disease According to the Study ORACLE II
  4. The prevalence of pathogenic variants in the BMPR2 gene in patients with the idiopathic pulmonary arterial hypertension in the Russian population: sequencing data and meta-analysis
  5. Malignancies after kidney transplantation: results of a 34-year population-based study
  6. Severely Ill COVID-19 Patients May Exhibit Hypercoagulability Despite Escalated Anticoagulation
  7. Risk factors for new-onset diabetes after transplantation in kidney transplant recipients: own data and meta-analysis
  8. Critically Ill COVID-19 Patients May Exhibit Plasma Hypercoagulability Despite Escalated Anticoagulation
  9. Clinical Features and Prospective Outcomes of Thin-Filament Hypertrophic Cardiomyopathy: Intrinsic Data and Comparative Insights from Other Cohorts
  10. Which scale is best to assess the risk of upper gastrointestinal bleeding in patients with stable coronary artery disease in the Russian population?
  11. Predictive value of left ventricular global function index in patients with aortic stenosis
  12. Clinical and Genetic Landscape Hypertrophic Cardiomyopathy on a Russian Single-Center Cohort Study
  13. Cardiology 2023: the time of genetics
  14. Assessment and modification of cardiovascular risk in non-cardiac surgery. Clinical guidelines 2023
  15. Results of a pilot clinical trial of the safety and efficacy of an original glycoprotein IIb/IIIa receptor inhibitor in acute coronary syndrome
  16. Lipoprotein (a) as a marker of hereditary lipid metabolism disorders in patients with early manifestation of coronary artery disease
  17. A rare variant in the TTR gene (p.E112K) is associated with systemic amyloidosis and a new symptom – skin hyperemia in response to ethanol intake: family segregation analysis, literature review, and a clinical case. Case report
  18. The levels of certain circulating microRNAs in hypertrophic cardiomyopathy are associated with echocardiographic parameters
  19. Mortality among kidney transplant recipients with SARS-CoV-2: a systematic review and meta-analysis of cohorts and clinical registries
  20. Mortality in kidney transplant recipients: a systematic review and meta-analysis of cohorts and clinical registries
  21. Novel Genes Involved in Hypertrophic Cardiomyopathy: Data of Transcriptome and Methylome Profiling
  22. Overlapping Phenotype of Adult-Onset ALPK3-Cardiomyopathy in the Setting of Two Novel Variants
  23. A survey of physician opinions in Russia in the field of pharmacogenetics of cardiovascular disease
  24. Left ventricular global function index and peculiarities of daily blood pressure profile in patients with arterial hypertension
  25. Molecular cardiology: from decoding the genetic nature and mechanisms of the diseases development to the introduction into the clinic
  26. Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis)
  27. Prospects for Using Chromatography–Mass Spectrometry for the Determination of Lipids in Clinical Cardiolipidology
  28. Circulating miR-499a-5p Is a Potential Biomarker of MYH7—Associated Hypertrophic Cardiomyopathy
  29. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy
  30. Left ventricular global function index as a predictor of adverse cardiovascular events in patients with acute coronary syndrome
  31. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy
  32. Visit-to-visit blood pressure variability in patients after acute coronary syndrome
  33. Changes in plasma sphingolipid levels against the background of lipid-lowering therapy in patients with premature atherosclerosis
  34. Pitavastatin: focus on safety and drug interactions
  35. Prevalence of hereditary factors in different age groups in patients with acute coronary syndrome
  36. Risk Stratification after an Acute Coronary Syndrome: Significance of Antithrombotic Therapy
  37. Using the ORACLE Risk Score to Assess Hemorrhagic Risk in Patients with Acute Coronary Syndrome and Atrial Fibrillation
  38. RESULTS OF MULTICENTER MONITORING OF HEMOSTASIS PARAMETERS IN PATIENTS WITH COVID-19
  39. Bleeding risk scales in patients with acute coronary syndrome: place of the ORACUL scale
  40. Can left ventricular global function index be a novel marker of unfavorable outcome in patients with acute coronary syndrome
  41. Contribution of electrocardiography to the diagnosis of cardiomyopathies and athletic heart syndrome
  42. Inherited thrombophilia and venous thromboembolism: testing rules in clinical practice
  43. Changes in the management of patients with acute coronary syndrome – have the disease outcomes changed?
  44. The Risk of Developing Ischemic Stroke in Patients After Exacerbation of Ischemic Heart Disease
  45. Recommendations of the Eurasian Arrhythmology Association (EURA) for the diagnosis and treatment of patients with arrhythmias and conduction disorders during the COVID-19 pandemic
  46. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients
  47. Bleeding rate and diagnostic value of different hemorrhagic risk scores in certain clinical groups of patients with acute coronary syndrome
  48. Cardiology: genetics’ time
  49. Lipidome features in patients with different probability of family hypercholesterolemia
  50. External validation of the ORACLE bleeding risk score using the database of the RECORD 3 registry
  51. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF
  52. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation
  53. Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5)
  54. A clinical case of hypertrophic cardiomyopathy and family hyperlipidemia
  55. Ticagrelor in Patients with Stable Coronary Disease and Diabetes
  56. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
  57. Participation of Sphingolipids in the Pathogenesis of Atherosclerosis
  58. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF
  59. VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY AND RISK OF ALL-CAUSE DEATH
  60. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation
  61. Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes
  62. Bleeding risk factors in patients with acute coronary syndrome: data from observational studies ORACUL II
  63. Physicians' guideline adherence is associated with long‐term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry
  64. Rationale, Design, and Baseline Characteristics of THEMIS: Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study
  65. Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry
  66. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation
  67. Psychosomatic Disorders in Patients with Pulmonary Hypertension: Impact on Treatment Adherence
  68. Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry
  69. Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan ― Insights From GARFIELD-AF ―
  70. Polymorphism of TNF gene in acute coronary syndrome patients: data from the registries ORACLE I and ORACLE II
  71. Targeted sequencing in patients with clinically diagnosed hereditary lipid metabolism disorder and acute coronary syndrome
  72. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry
  73. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry
  74. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
  75. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
  76. Screening of familial hypercholesterolemia among patients in age under 40 years old exposed by duplex scanning of carotid arteries, by the local registry data
  77. Polymorphism of ANXA2 gene may accelerate vulnerability and calcinosis in patients with coronary atherosclerosis
  78. IL-10 GENE POLYMORPHISM AND STROKE RISK IN PATIENTS WITH CORONARY ARTERY DISEASE
  79. STRATEGY TO MINIMIZE THE BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION WHO RECEIVE COMBINED ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION
  80. Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
  81. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants
  82. GENETIC MARKERS OF MYOCARDIAL FIBROSIS: OPPORTUNITY TO PREDICT ADVERSE OUTCOMES IN AORTIC STENOSIS
  83. IS IT SAFE TO SWITCH OAC IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION? RESULTS FROM A RE-DUAL PCI SUBANALYSIS
  84. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation
  85. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
  86. Family History of Cardiovascular Disease in Patients With Early Development of Acute Coronary Syndrome
  87. Possibilities of molecular biopsy in differential diagnosis of pulmonary arterial hypertension: case description and literature review
  88. Risk of Stroke After Exacerbation of Ischemic Heart Disease: Data of 3‑Years Follow-up
  89. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
  90. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
  91. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry
  92. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation
  93. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
  94. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
  95. [PP.30.09] KIF6 GENE POLYMORPHISM IS ASSOCIATED WITH ARTERIAL RESISTANCE AND ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION
  96. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial
  97. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
  98. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
  99. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
  100. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves
  101. Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry
  102. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease ― Results From EMPA-REG OUTCOME® ―
  103. OUP accepted manuscript
  104. OUP accepted manuscript
  105. GENETIC POLYMORPHISM OF THE INFLAMMATORY CYTOKINE GENES AND ARTERIAL WALL PROPERTIES IN HYPERTENSIVE PATIENTS
  106. PRIMARY (GENETICALLY DETERMINED) DILATION CARDIOMYOPATHY IN A PATIENT WITH NOVEL MUTATION OF LAMIN GENE: CLINICAL AND MORPHOLOGICAL MANAGEMENT
  107. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation
  108. Evolving quality standards for large-scale registries: the GARFIELD-AF experience
  109. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry
  110. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry
  111. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
  112. Multiple coronary fistulae into left ventricle as a rare cause of myocardial ischemia
  113. [PP.07.21] PARG GENE POLYMORPHISM IS ASSOCIATED THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN ARTERIAL HYPERTENSION
  114. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events
  115. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
  116. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF
  117. A Novel Hypoxia-Inducible Factor−Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial
  118. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists
  119. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48
  120. The use of optimal partitionings for multiparameter data analysis in clinical trials
  121. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
  122. Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction With ST-Segment Elevation After Prehospital Thrombolysis
  123. Using Necrosis Biomarkers for the Early Diagnosis of Myocardial Infarction in Modern Conditions
  124. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
  125. Early Systolic Dysfunction of Left Ventricular Myocardium Is Reflected On Electrocardiogram of Patients With Aortic Stenosis
  126. Genetic Features of Factors of Inflammation and Fibrosis – Possible Common Pathway of Formation of Predisposition to Atrial Fibrillation and Chronic Obstructive Pulmonary Disease
  127. MOLECULAR-GENETIC FACTORS, ASSOCIATED WITH AORTIC STENOSIS DEVELOPMENT
  128. Atrial Fibrillation in Patients With Chronic Obstructive Pulmonary Disease Is Associated With Polymorphism of Interleukin 6 Gene
  129. GENETIC POLYMORPHISM OF INFLAMMATORY FACTORS IS ASSOCIATED WITH THROMBOEMBOLIC COMPLICATIONS OF ATRIAL FIBRILLATION
  130. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
  131. THE REVOLUTION, WE HAVE ALMOST OVERSLEPT
  132. Biomarkers in Heart Failure: Apelin Level Is not Associated With Presence and Severity of the Disease
  133. Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation
  134. Late Silent Stent Abscess
  135. Chronic Thromboembolic Pulmonary Hypertension
  136. Current Aspects of Fibrinolysis
  137. Сhronic Thromboembolic Pulmonary Hypertension
  138. Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome
  139. Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
  140. An intuitive risk factors search algorithm: usage of the Bayesian network technique in personalized medicine
  141. Laboratory Monitoring of the Efficacy and Safety of Anticoagulants
  142. Degenerative Aortic Stenosis: Prediction of Poor Prognosis by 2D Left Ventricular Longitudinal Strain in Non-Operated Patients
  143. Dabigatran in Prevention of Stroke in Atrial Fibrillation: Three Years of Clinical Application
  144. Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome
  145. Edoxaban versus Warfarin in Patients with Atrial Fibrillation
  146. Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
  147. ISSUES OF ANTICOAGULANT TREATMENT MANAGEMENT
  148. WARFARIN IN PATIENTS WITH CARDIOEMBOLIC STROKE
  149. Polymorphic markers Ala455Val of the THBD gene and Arg353Gln of the F7 gene and genetic association with unfavorable outcomes of coronary atherosclerosis in patients with a history of acute ischemic heart disease
  150. Rationale, design, and results from RENO-DEFEND 1: A randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure
  151. 602 ASSOCIATION OF POLYMORPHIC MARKERS C3386A OF HMGCR GENE AND G(-198)A OF FDFT1 GENE WITH CORONARY ARTERY DISEASE
  152. 611 DEVELOPMENT OF GENDER PRESPECIFIED PREDICTION MODEL BASED ON BAYESIAN BELIEVE NETWORKS METHOD FOR RISK ESTIMATION AFTER ACUTE CORONARY SYNDROME
  153. 869 DEVELOPMENT OF GENDER PRESPECIFIED PREDICTIVE MODEL BASED ON BAYESIAN BELIEVE NETWORKS METHOD FOR UNFAVOURABLE OUTCOMES AFTER ACUTE CORONARY SYNDROME
  154. 634 GENDER DEPENDENT ASSOCIATION BETWEEN KIF6 POLYMORPHISM AND RISK OF UNFAVORABLE OUTCOME IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME
  155. 639 POLYMORPHIC MARKERS OF THBD AND PROC GENES AND GENETIC PREDISPOSITION TO UNFAVOURABLE OUTCOMES IN PATIENTS AFTER ACUTE CORONARY SYNDROME
  156. Ispol'zovanie rozuvastatina v lechenii bol'nykh gruppy riska sosudistykh oslozhneniy ateroskleroza.
  157. PECULIAR PROPERTIES OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION. IS IT POSSIBLE TO DO THE TREATMENT SAFE?
  158. Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure
  159. The polymorphisms G(−174)C in IL6 gene and G(−1082)A in IL10 gene are associated with poor outcomes in patients with acute coronary syndrome
  160. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
  161. Association of the polymorphic markers G(−455)A in the FGB gene and C(−1654)T in the PROC gene with hereditary predisposition to unfavourable outcome in patients with history of acute coronary syndrome
  162. MS217 ASSOCIATION OF THE CHOLESTEROL ESTER TRANSFER PROTEIN GENE (CETP) WITH CORONARY ARTERY DISEASE
  163. MS216 IL6 AND IL10 GENES ARE ASSOCIATED WITH UNFAVOURABLE OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROME
  164. Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population
  165. Advanced age, low left atrial appendage velocity, and Factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation
  166. Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effe...
  167. THE MODERN ASPECTS OF CLOPIDOGREL USE
  168. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
  169. Chronic Thromboembolic Pulmonary Hypertension
  170. The PROTECT Pilot Study: A Randomized, Placebo-Controlled, Dose-Finding Study of the Adenosine A1 Receptor Antagonist Rolofylline in Patients With Acute Heart Failure and Renal Impairment
  171. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
  172. Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure
  173. The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population
  174. Association of GNB3 gene C825T polymorphism with coronary heart disease
  175. Association ofCYP2D6andADRB1genes with hypotensive and antichronotropic action ofbetaxololin patients with arterial hypertension
  176. Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
  177. Mo-P6:387 Genetic predisposition to early onset of coronary artery disease in Russian patients
  178. Mo-P6:455 Genetic predisposition to unfavourable outcomes in patients with unstable angina
  179. W03-P-008 Genetic basis of inherited predisposition to coronary artery disease
  180. Association of Polymorphic Marker A1/A2 of Gene ITGB3 with Coronary Artery Disease and Myocardial Infarction
  181. Association of Polymorphic Marker G(–455)A of Gene FGB with Coronary Artery Disease
  182. ASSOCIATION OF THE POLYMORPHIC MARKERS OF MTHFR, EDN1, CYP11B2, PPARA AND PPARG2 GENES WITH THE SEVERITY OF ESSENTIAL HYPERTENSION
  183. Anticoagulant properties of the endothelium studied by the standard venous occlusion test